{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:30:23Z","timestamp":1771860623969,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Health and Medical Research Council Research Fellowship","award":["#1013803"],"award-info":[{"award-number":["#1013803"]}]},{"name":"National Health and Medical Research Council Research Fellowship","award":["#1041472"],"award-info":[{"award-number":["#1041472"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p><jats:italic>Use of opioid agonist treatments for prescription opioid (PO) dependence is rapidly increasing. Current guidelines are based on research with heroin users. This study aimed to examine methadone and buprenorphine dose requirements for PO\u2010dependent people.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Methods<\/jats:title><jats:p><jats:italic>A retrospective case series of PO\u2010dependent patients entering methadone and buprenorphine treatment. Daily oral morphine equivalent (OME) doses at baseline were calculated using standard dose conversion calculations. Dose conversion tables were used to estimate opioid agonist doses, based on starting dose of PO. Baseline methadone and buprenorphine dose at days 7 and 28 were examined. Linear models were fit to the data.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>Participants (n\u2009=\u200944) were 67% male, mean age 41\u2009years (SD 10\u2009years); 69% reported a pain condition. The methadone group (n\u2009=\u200921) had a mean PO dose of 704.5\u2009mg OME (SD 783.5\u2009mg) prior to treatment, and mean methadone dose of 45.3\u2009mg (SD 13.1\u2009mg) at day 7 and 61.6\u2009mg (SD 20.8\u2009mg) at day 28. The buprenorphine group (n\u2009=\u200923) had a mean PO dose of 771.7\u2009mg OME (SD 867.7\u2009mg) prior to treatment, with a mean dose of 14.6\u2009mg (SD 8.3\u2009mg) at day 7 and 18.1 (SD 8.9\u2009mg) at day 28. Linear relationships were not found between OME and opioid agonist dose.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:italic>Opioid agonist dosages varied substantially between individuals, and from predicted dosages based on dose conversion tables. Use of conversion tables to guide selection of opioid agonist dosage may compromise patient safety.<\/jats:italic> [Nielsen S, Bruno R, Degenhardt L, Demirkol A, Lintzeris N. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series Drug Alcohol Rev 2017;36:311\u2013316]<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.12418","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T11:43:12Z","timestamp":1465299792000},"page":"311-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series"],"prefix":"10.1111","volume":"36","author":[{"given":"Suzanne","family":"Nielsen","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Centre University of New South Wales  Sydney Australia"},{"name":"University of Sydney, Discipline of Addiction Medicine  Sydney Australia"},{"name":"Drug and Alcohol Services South Eastern Sydney Local Health District  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6673-833X","authenticated-orcid":false,"given":"Raimondo","family":"Bruno","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Centre University of New South Wales  Sydney Australia"},{"name":"School of Medicine University of Tasmania  Hobart Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Centre University of New South Wales  Sydney Australia"},{"name":"School of Population and Global Health University of Melbourne  Melbourne Australia"},{"name":"Murdoch Children's Research Institute Royal Children's Hospital  Melbourne Australia"},{"name":"Department of Global Health, School of Public Health University of Washington  Seattle USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apo","family":"Demirkol","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services South Eastern Sydney Local Health District  Sydney Australia"},{"name":"School of Public Health and Community Medicine University of New South Wales  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"University of Sydney, Discipline of Addiction Medicine  Sydney Australia"},{"name":"Drug and Alcohol Services South Eastern Sydney Local Health District  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Substance Abuse and Mental Health Services Administration.Substance abuse treatment admissions involving abuse of pain relievers: 1998 and 2008. Office of Applied Studies Substance Abuse and Mental Health Services Administration (SAMHSA).2010."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.004"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.596974"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.10.014"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00015-2"},{"key":"e_1_2_7_7_1","first-page":"68","article-title":"Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids","volume":"55","author":"Sproule B","year":"2009","journal-title":"Can Fam Physician"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002208"},{"key":"e_1_2_7_9_1","first-page":"7","article-title":"Buprenorphine induction and stabilisation in the treatment of opiate dependence","volume":"7","author":"Doran CM","year":"2005","journal-title":"Heroin Add & Rel Clin Probl"},{"key":"e_1_2_7_10_1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick RP","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2013.01.028"},{"key":"e_1_2_7_12_1","unstructured":"NielsenS DegenhardtL HobanB GisevN.Comparing opioids: a guide to estimating oral morphine equivalents (OME) in research. Technical Report No. 329. Sydney: National Drug and Alcohol Research Centre University of New South Wales;2014."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.06.002"},{"key":"e_1_2_7_14_1","unstructured":"GowingL AliR DunlopA FarrellM LintzerisN.National Guidelines for Medication\u2010assisted Treatment of Opioid Dependence.2014."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12224"},{"key":"e_1_2_7_16_1","unstructured":"CohenJ.Statistical Power Analysis for the Behavioral Sciences 2nd edn.Hillsdale NJ:Lawrence Earlbaum Associates 1988."},{"key":"e_1_2_7_17_1","unstructured":"Center for Substance Abuse Treatment.Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40: Substance Abuse and Mental Health Services Administration;2004."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311406577"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12315"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdar.12418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdar.12418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.12418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:34:45Z","timestamp":1696314885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.12418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/dar.12418"],"URL":"https:\/\/doi.org\/10.1111\/dar.12418","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]},"assertion":[{"value":"2015-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}